Proactive Investors - Run By Investors For Investors

Hemispherx treats first patient with cancer drug Ampligen in Phase 2 clinical trials

The study looks at the effectiveness of ampligen in combination with the drug pembrolizumab at treating ovarian cancer
cancer cells
Hemispherx believes that Ampligen could have anti-viral and anti-cancer properties

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) took a key step forward in its Phase 2 clinical trial on Wednesday after it announced that the first patient has been treated with its flagship drug Ampligen.

The study looks at the effectiveness of ampligen in combination with the drug pembrolizumab at treating ovarian cancer. It is being run out of the University of Pittsburgh Medical Center.

Shares of Hemispherx jumped 21.8% on Wednesday afternoon in New York.

READ: Hemispherx Biopharma’s well-funded to take promising cancer drug Ampligen through clinical trials

Florida-based Hemispherx believes that Ampligen could have anti-viral and anti-cancer properties. Prior clinical trials of the drug looked at patients with renal cell carcinoma and malignant melanoma.

The Phase 1 initial study indicated that Ampligen is generally well-tolerated when administrated through the abdominal cavity.

The Phase 2 clinical trials are being run under the leadership of principal investigator Dr. Robert Edwards and is expected to treat 45 patients.

Clinically significant

 “Ampligen has the potential to be clinically significant because a robust killer T-cell population in the tumor microenvironment without attracting Treg cells is important to help optimize checkpoint blockade induced tumor shrinkage," said Dr. Edwards in a statement.

Ovarian cancer is expected to be the cause of death for 152,000 people this year, according to Hemispherx.

“With this new large-scale study funded by an industry grant, Hemispherx and the team at Magee-Women's Hospital of the University of Pittsburgh School of Medicine are focused on developing a potentially life-saving therapy to meet this critical and unmet medical need," said CEO Thomas K. Equels.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

View full HEB profile View Profile

Hemispherx Biopharma Inc Timeline

Related Articles

Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
cancerous cells
March 08 2019
A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen
A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use